After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...